#study

This $14 million research project aims to find out. Here’s why it’s based in Miami.

A recent review of 54 studies indicates that people living with HIV are at high risk for experiencing cardiac dysfunction.

People with the chronic inflammatory lung disease are about two times more likely to have a heart attack.

The Chicago-based HIV-prevention effort garnered about 41 million views in its first four months alone. And that’s not all.

One hundred twenty volunteers to enroll in Seattle-area study of cancer-related gene mutations

A recent meta-analysis found that the addition of hepatitis C raises a cardiovascular disease risk already elevated by HIV.

Among people with HIV who don’t have hepatitis C virus, various factors raise the risk of liver fibrosis (scarring) and fatty liver disease.

Even when HIV is fully suppressed, the virus is associated with as much as double the risk of cardiovascular disease (CVD).

Curing HCV in those coinfected with HIV provides the greatest chance to reduce the risk of death among those who have advanced fibrosis.

A recent study tested the long-acting injectable antiretrovirals cabotegravir and Edurant (rilpivirine) given every four or eight weeks.

Another study finds that there is no HIV transmission when viral load is fully suppressed.

ViiV Healthcare has applied to the FDA for approval of the first two-drug antiretroviral (ARV) regimen to treat HIV.

Almost all of a large group of inner-city Baltimore individuals coinfected with HIV and HCV were recently cured of hep C.

Researchers have succeeded in immunizing calves and prompting them to produce so-called broadly neutralizing antibodies against HIV.

Women taking various forms of hormonal contraceptives can likely combine them safely with antiretrovirals.

The single-tablet HIV treatment regimen includes the experimental integrase inhibitor bictegravir and the contents of Descovy.